Mr. Ray Dupuis reports

KANE BIOTECH ANNOUNCES $250,000 INSIDER LOAN

Kane Biotech Inc. has accepted an unsecured loan in the principal amount of $250,000 from Philip Renaud, chair of the company's board of directors and an approved control person of the company.

The loan does not bear interest and is repayable on demand. No bonus was paid or is payable by the company in connection with the loan. The company intends to use the proceeds for general working capital and corporate purposes and intends to repay the loan from future capital raises or general revenue.

The loan constitutes a "related party transaction" under Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions and TSX Venture Exchange Policy 5.9. The company is relying on the exemptions from the formal valuation and minority shareholder approval requirements in sections 5.5(a) and 5.7(1)(a) of MI 61-101 because the fair market value of the loan does not exceed 25 per cent of the company's market capitalization.

"This unsecured loan provides Kane Biotech with additional working capital as we continue to advance our corporate and commercial priorities," said Mr. Renaud. "I remain committed to supporting the company as management pursues its strategy and longer-term financing alternatives".

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost.

We seek Safe Harbor.